ClinicalTrials.gg
Not yet recruitingNCT06912412Updated Apr 4, 2025

Community-Based Remote Cardiac Rehabilitation Program for Pediatric Patients With Complex Congenital Heart Disease

An interventional study of Community-based supervised remote cardiac rehabilitation and Home-based cardiac rehabilitation program in Congenital Heart Disease (CHD), Complex Congenital Heart Disease and Congenital Heart Disease in Children, sponsored by Seoul National University Hospital. Not yet recruiting at 1 site in Korea, Republic of. Open to participants aged 8 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-04-04.

Sponsored by Seoul National University Hospital · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
8 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Heart Defects, Congenital with a site in Korea, Republic of — 2 open to participants now, 2 under way, none of them phase 3. Heart Defects, Congenital · Korea, Republic of.

Started
2025
the only one that year
No phase
8 of 17
2 open now
Registered
17th of 17
by date
Lead sponsor
7 of 17
Seoul National University Hospital

Among the 17 studies in Heart Defects, Congenital with a site in Korea, Republic of, this one is the only one that started in 2025, is one of 8 with no phase, and was the 17th registered.

Heart Defects, Congenital

992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.

Browse Heart Defects, Congenital studies →

Open to participants now

2 of the 17 studies in Heart Defects, Congenital with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.

This study: 8 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Heart Defects, Congenital with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This study is to develop a 12-week community-based remote cardiac rehabilitation program for pediatric patients with complex congenital heart disease and to assess its validity and safety.

For these children, a multidisciplinary approach including pediatric rehabilitation medicine, pediatric thoracic surgery, pediatrics, pediatric psychiatry, sports science, and nutrition is essential, but such comprehensive services are rarely available in Korea. As a result, pediatric cardiac rehabilitation at the community level is nearly nonexistent. Recent long-term retrospective cohort studies suggest that maintaining regular physical activity and aerobic capacity from early childhood significantly reduces future cardiovascular complications, emphasizing the importance of early pediatric cardiac rehabilitation. However, participation in existing programs is low due to limited accessibility.

The investigators hypothesize that a community-based remote cardiac rehabilitation program for these patients is both valid and safe. Participants will be children aged 8-18 years diagnosed with complex congenital heart disease , at least 3 months post-surgery, and stable cardiovascular status.

Interventions include supervised and self-directed cardiac rehabilitation exercises. Monitoring (heart rate, SpO2, ECG) will be performed in real-time, with non-real-time data collection of physical activity using smartwatches. The intervention lasts 12 weeks with a 12-week follow-up.

Validity measures include baseline evaluation, adherence, dropout rate, participant and parent satisfaction, and changes in cardiopulmonary exercise capacity, physical activity, body composition, fitness (6-minute walk, strength, flexibility, respiratory muscle strength), and questionnaires (physical activity, quality of life, exercise satisfaction, depression, psychological state).

Safety will be assessed by monitoring adverse events, vital signs, fatigue (Borg scale), and pain before and after exercise.

03

Conditions studied

  • Congenital Heart Disease (CHD)
  • Complex Congenital Heart Disease
  • Congenital Heart Disease in Children

Keywords

  • Complex congenital heart disease
  • remote cardiac rehabilitation
  • cardiac rehabilitation
  • children cardiac rehabilitation
04

Who can participate

Ages eligible
8 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged between 8 and 18 years
  2. Diagnosed with complex congenital heart disease (Complex CHD) and have undergone surgery
  3. At least 3 months post-cardiac surgery with a stable hemodynamic status
  4. Capable of using remote programs (e.g., mobile apps, video-conferencing platforms) at home, with technical support from a caregiver
  5. Either the participant or their caregiver agrees to study participation and has signed the form

Exclusion criteria

Exclusion Criteria:

  1. Patients with uncontrolled arrhythmias, acute heart failure, myocarditis, pericarditis, or other ongoing cardiovascular conditions.
  2. Patients who are unable to exercise independently due to neurological or musculoskeletal disorders.
  3. Patients who cannot understand or carry out remote rehabilitation program instructions due to cognitive impairment.
  4. Patients showing levels of depression or anxiety on the CDI-2 or RCMAS.
  5. Patients who cannot cooperate with required study assessments (e.g., CPET, , 6MWT).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Community-based remote cardiac rehabilitation group

    The group is provided with a single session of supervised remote cardiac rehabilitation session per week, and 4 sessions of home-based rehabilitation. During the supervised remote session, the EKG signal, heart rate and SpO2 of the participants are monitored in real-time using a single lead EKG and SpO2 monitor. Their activity levels are also recorded using a smartwatch, in number of steps and minutes in moderate-vigorous physical activity time

    Other: Community-based supervised remote cardiac rehabilitation · Other: Home-based cardiac rehabilitation program

Interventions

  • OtherCommunity-based supervised remote cardiac rehabilitation

    Community-based supervised remote cardiac rehabilitation begins with a weekly session led by exercise specialists, who use remote-based materials to match each participant's target heart rate and rate of perceived exertion (RPE). During these sessions, participants perform aerobic, strength, and respiratory exercises using progressive overload principles, with devices such as the POWERbreathe Plus supporting individualized respiratory training. Depending on the risk classification for each participant, they will be provided with different intensity of exercises (depending on their measured HR max, HRR, and/or RPE).

  • OtherHome-based cardiac rehabilitation program

    Beyond the single supervised session, participants undertake four weekly home-based sessions. * Low-Risk Group: Aerobic and respiratory exercises are performed four times per week, plus strength training once or twice weekly. Each 60-minute session includes a 10-minute warm-up, 40-minute main exercise, and 10-minute cool-down. Indoor sessions use remote exercise content and respiratory training devices, while outdoor activities may involve walking, jogging, cycling, or swimming. Exercises progress in duration, intensity, and resistance. * Moderate-Risk Group: Aerobic and respiratory exercises are done four times per week with an RPE of 8-13. Intensity and duration increase gradually, contingent on symptom stability and improved endurance. * High-Risk Group: Aerobic and respiratory sessions occur four times a week at an RPE of 8-10, each lasting around 30 minutes (5-minute warm-up, 20-30-minute main exercise, 5-minute cool-down).

06

What researchers measure

Primary outcomes

  1. Drop-out rate

    Time frame: baseline, 12 weeks after, 24 weeks after follow-up

  2. Attendance rate

    Time frame: baseline, 12 weeks after, 24 weeks after follow-up

Secondary outcomes

  1. oxygen consumption, VO2

    Oxygen consumption (VO2) refers to the rate at which the body takes in and uses oxygen.

    Time frame: baseline, 12 weeks after, 24 weeks after follow-up

  2. maximal oxygen consumption, VO2 max

    Maximal oxygen consumption (VO2 max) represents the highest rate at which an individual can take in, transport, and utilize oxygen during maximal or exhaustive exercise.

    Time frame: baseline, 12 weeks after, 24 weeks after follow-up

  3. Respiratory exchange rate, RER

    Respiratory Exchange Ratio (RER) is the ratio of the volume of carbon dioxide produced (VCO2) to the volume of oxygen consumed (VO2) in the body. RER = VCO2 / VO2

    Time frame: baseline, 12 weeks after, 24 weeks after follow-up

  4. minute ventilation (VE)

    minute ventilation (VE) refers to the total volume of air inhaled or exhaled by an individual per minute. VE = Tidal Volume (VT) x Respiratory Rate (RR)

    Time frame: baseline, 12 weeks after, 24 weeks after follow-up

  5. ventilation effectiveness, VE/VO2

    Ventilation effectiveness, when expressed as the ratio of minute ventilation (VE) to oxygen consumption (VO2) (VE/VO2), represents the volume of air that needs to be breathed to consume one liter of oxygen.

    Time frame: baseline, 12 weeks after, 24 weeks after follow-up

  6. oxygen per pulse, O2 pulse

    Time frame: baseline, 12 weeks after, 24 weeks after follow-up

  7. oxygen saturation, SpO2

    Time frame: baseline, 12 weeks after, 24 weeks after follow-up

  8. maximal heart rate during exercise, HR max

    Time frame: baseline, 12 weeks after, 24 weeks after follow-up

  9. heart rate by exercise intensity

    Time frame: baseline, 12 weeks after, 24 weeks after follow-up

  10. average number of steps for 7 days using smartwatch

    Time frame: baseline, 12 weeks after, 24 weeks after follow-up

  11. average moderate-vigorous physical activity time for 7days using smartwatch, minutes

    Time frame: baseline, 12 weeks after, 24 weeks after follow-up

  12. skeletal muscle mass (kg)

    Time frame: baseline, 12 weeks after, 24 weeks after follow-up

  13. body fat mass (kg)

    Time frame: baseline, 12 weeks after, 24 weeks after follow-up

  14. body fat percentage

    Time frame: baseline, 12 weeks after, 24 weeks after follow-up

  15. Abdominal fat percentage

    Time frame: baseline, 12 weeks after, 24 weeks after follow-up

  16. Intracellular moisture, extracellular moisture

    Time frame: baseline, 12 weeks after, 24 weeks after follow-up

  17. Radial artery pulse wave amplification index: Augmentation index (AIx@75 index)

    arterial stiffness and wave reflection at a heart rate of 75 beats per minute

    Time frame: baseline, 12 weeks after, 24 weeks after follow-up

  18. Carotid-femoral pulse wave velocity, c-f PWV

    Carotid-femoral pulse wave velocity (c-f PWV) is a non-invasive medical test used to assess arterial stiffness, which is a measure of how rigid or flexible the arteries are. c-f PWV = Distance between carotid and femoral sites / Time difference between pulse wave arrival at the two sites.

    Time frame: baseline, 12 weeks after, 24 weeks after follow-up

  19. Flow-mediated dilation, FMD%

    Flow-Mediated Dilation (FMD%) is a non-invasive ultrasound technique used to assess endothelial function, which is the ability of the inner lining of arteries (the endothelium) to relax and contract properly. FMD% specifically measures the percentage change in the diameter of an artery in response to an increase in blood flow

    Time frame: baseline, 12 weeks after, 24 weeks after follow-up

  20. 6 minutes walk test

    total distance in meters

    Time frame: baseline, 12 weeks after, 24 weeks after follow-up

  21. lower limb muscle strength test (peak torque/BW)

    Time frame: baseline, 12 weeks after, 24 weeks after follow-up

  22. Upper extremity strength test: grip force (kg)

    Time frame: baseline, 12 weeks after, 24 weeks after follow-up

  23. Flexibility check: Flexibility distance (cm)

    Time frame: baseline, 12 weeks after, 24 weeks after follow-up

  24. Respiratory muscle strength test (MIP mmH2O)

    Maximal Inspiratory Pressure (MIP) is a measurement in assessing the strength of inspiratory muscles. It reflects the strength of the diaphragm and other inspiratory muscles.

    Time frame: baseline, 12 weeks after, 24 weeks after follow-up

  25. Global Physical Activity Questionnaire

    The Global Physical Activity Questionnaire (GPAQ) doesn't have a fixed minimum and maximum score. A score of 0 would indicate no reported physical activity. Higher scores means a better outcome in terms of physical activity levels.

    Time frame: baseline, 12 weeks after, 24 weeks after follow-up

  26. Pediatric Quality of Life Inventory™ (PedsQL™) for subjects and parents

    Minimum Value (Total Score): 0 Maximum Value (Total Score): 100 Higher Scores Mean: A better outcome. Higher scores on the PedsQL™ indicate a better health-related quality of life, as reported by either the child/adolescent or their parent.

    Time frame: baseline, 12 weeks after, 24 weeks after follow-up

  27. Pediatric Quality of Life Inventory Cardiac, PedsQL™ Cardiac

    Minimum Value (Total Score): 0 Maximum Value (Total Score): 100 Higher Scores Mean: A better outcome. Higher scores on the PedsQL™ Cardiac module indicate a better health-related quality of life for the child with a cardiac condition.

    Time frame: baseline, 12 weeks after, 24 weeks after follow-up

  28. Program satisfactory survey

    Time frame: 12 weeks

  29. Resilience Scale for Youth, RS-Y

    Minimum Value: 25 Maximum Value: 125 Higher Scores Mean: A better outcome. Higher scores on the Resilience Scale for Youth indicate a higher level of resilience in the individual.

    Time frame: baseline, 12 weeks after, 24 weeks after follow-up

  30. Child Behavior Checklist for parents, CBCL

    Minimum Value : 0 Maximum Value : 118 Higher Scores Mean: A worse outcome. Higher scores on the Total Problems scale of the CBCL indicate a greater number and severity of reported behavioral and emotional problems in the child.

    Time frame: baseline, 12 weeks after, 24 weeks after follow-up

  31. blood pressure by exercise intensity

    Time frame: baseline, 12 weeks after, 24 weeks after follow-up

  32. Children's Depression Inventory 2, K-CDI-2:SR

    Minimum Value: 0 Maximum Value: 54 Higher Scores Mean: A worse outcome. Higher scores on the K-CDI-2:SR indicate higher levels of reported depressive symptoms.

    Time frame: baseline, 12 weeks after, 24 weeks after follow-up

  33. Revised Children's Manifest Anxiety Scale 2, RCMAS-2

    Minimum Value: 0 Maximum Value: 49 Higher Scores Mean: A worse outcome. Higher scores on the RCMAS-2 indicate higher levels of reported anxiety.

    Time frame: baseline, 12 weeks after, 24 weeks after follow-up

  34. Incidence proportion of adverse events and harm during exercise

    Incidence proportion of participants with exercise-related adverse events as assessed by CTCAE v4.0

    Time frame: 12 weeks after, 24 weeks after follow-up

  35. Incidence rate of adverse events and harm during exercise

    Incidence rate of participants with exercise-related adverse events as assessed by CTCAE v4.0

    Time frame: 12 weeks after, 24 weeks after follow-up

  36. Changes in pre- and post-workout heart rate

    Time frame: up to 12 weeks

  37. Changes in pre- and post-workout oxygen saturation (SpO2)

    Time frame: up to 12 weeks

  38. Changes in pre- and post-workout respiratory rate

    Time frame: up to 12 weeks

  39. Rate of Perceived Exertion, Borg scale

    Unabbreviated Scale Title: Rate of Perceived Exertion (RPE) Scale Minimum Value: 6 Maximum Value: 20 Higher Scores Mean: A worse outcome. Higher numbers on the Borg scale indicate a greater feeling of exertion.

    Time frame: up to 12 weeks

  40. Upper extremity strength test: relative grip force (%)

    Time frame: baseline, 12 weeks after, 24 weeks after follow-up

  41. lower limb muscle strength test (peak torque)

    Time frame: baseline, 12 weeks after, 24 weeks after follow-up

  42. extracellular moisture ratio

    Time frame: baseline, 12 weeks after, 24 weeks after follow-up

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2025; primary completion for Dec 2028, 43 months later.

Of 208 non-industry interventional studies with no phase under Heart Defects, Congenital, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 43 months is above that.

Counting every sponsor, half of 226 studies reached it within 34 months; a quarter within 17 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2025
First posted
Apr 4, 2025
StartEst.
May 31, 2025
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2029
Last update
Apr 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06912412
Collaborators
University of Seoul
Responsible party
Woo Hyung Lee (Clinical associate professor, Seoul National University Hospital) — Principal investigator
First posted
Apr 4, 2025
Start date
May 31, 2025 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Apr 4, 2025

Study contacts

Sungbae Jo Research professor, Ph. D
Contact
rew277@gmail.com
82-10-9381-2299

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion